Exelixis Inc

Research Exelixis Inc (EXEL) on Bullrun: valuation model: 12.8% undervalued, market cap USD 13.64B, P/E 18.0. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerEXEL
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal12.8% undervalued
• Market capUSD 13.64B
• P/E18.0
• Financial periodFY2026
• RevenueUSD 2.32B
• Revenue growth7.0%
• Net incomeUSD 782.60M
• Free cash flowUSD 875.84M
• Gross margin96.4%

Valuation Snapshot

Bullrun's latest valuation model marks Exelixis Inc as 12.8% undervalued; latest market cap is USD 13.64B; P/E is 18.0.

About Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Frequently asked questions

Is Exelixis Inc overvalued or undervalued?

Bullrun's valuation model currently marks Exelixis Inc as 12.8% undervalued.

What is Exelixis Inc's market cap?

Exelixis Inc's market capitalization is USD 13.64B.

What is Exelixis Inc's P/E ratio?

Exelixis Inc's price-to-earnings (P/E) ratio is 18.0.

What does Exelixis Inc do?

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.